BioVaxys Technology Corp. (BIOV.CN)
CAD 0.06
(0.0%)
CAD 0.06
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -977.00 CAD | 99.31% |
| 2022 | -141.89 Thousand CAD | 76.08% |
| 2021 | -593.11 Thousand CAD | 75.52% |
| 2020 | -2.42 Million CAD | -958.21% |
| 2019 | -228.98 Thousand CAD | -1363.22% |
| 2018 | -15.64 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -867.01 Thousand CAD | -88642.07% |
| 2024 Q3 | -409.63 Thousand CAD | -332.21% |
| 2024 Q2 | -94.77 Thousand CAD | 89.07% |
| 2023 FY | -977.00 CAD | 99.31% |
| 2023 Q1 | -71.61 Thousand CAD | 49.53% |
| 2023 Q2 | -28.47 Thousand CAD | 60.23% |
| 2023 Q4 | -977.00 CAD | -130.97% |
| 2023 Q3 | -423.00 CAD | 98.51% |
| 2022 Q4 | -141.89 Thousand CAD | -263.39% |
| 2022 FY | -141.89 Thousand CAD | 76.08% |
| 2022 Q3 | -39.04 Thousand CAD | 65.62% |
| 2022 Q2 | -113.57 Thousand CAD | 23.77% |
| 2022 Q1 | -148.99 Thousand CAD | 74.88% |
| 2021 Q3 | -740.7 Thousand CAD | 46.32% |
| 2021 Q1 | -857.1 Thousand CAD | 64.63% |
| 2021 Q2 | -1.37 Million CAD | -61.0% |
| 2021 FY | -593.11 Thousand CAD | 75.52% |
| 2021 Q4 | -593.11 Thousand CAD | 19.93% |
| 2020 Q4 | -2.42 Million CAD | -290.75% |
| 2020 FY | -2.42 Million CAD | -958.21% |
| 2020 Q3 | -620.12 Thousand CAD | -269.27% |
| 2020 Q2 | -167.93 Thousand CAD | 20.16% |
| 2020 Q1 | -210.32 Thousand CAD | 8.15% |
| 2019 FY | -228.98 Thousand CAD | -1363.22% |
| 2019 Q3 | -261.43 Thousand CAD | 13.9% |
| 2019 Q1 | -334.96 Thousand CAD | 0.0% |
| 2019 Q2 | -303.64 Thousand CAD | 9.35% |
| 2019 Q4 | -228.98 Thousand CAD | 12.41% |
| 2018 FY | -15.64 Thousand CAD | 0.0% |
| 2018 Q3 | -970.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 99.219% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 97.815% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | 100.47% |
| ChitogenX Inc. | 3.84 Million CAD | 100.025% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | 100.043% |
| Defence Therapeutics Inc. | 1.68 Million CAD | 100.058% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 99.717% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | 100.344% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | 100.841% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 99.75% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | 101.67% |
| Doseology Sciences Inc. | -1.06 Million CAD | 99.908% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 100.033% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | 87.92% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 99.954% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 100.025% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 99.864% |